Logo

Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and Hematological Malignancies

Share this

Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and Hematological Malignancies

Shots:

  • The companies collaborated to evaluate ADG106 + Keytruda in dose-escalation and expansion clinical study to treat advanced or metastatic solid tumors & hematological malignancies
  • In preclinical studies- ADG106 showed antitumor activity and was well tolerated as a monothx. and in combination with other immuno-oncology therapies
  • ADG106 is a fully human- ligand-blocking- agonistic anti-CD137 IgG4 mAb engineered using its NEObody platform technology & is being evaluated in a P-Ib/II combination study for advanced solid tumors and r/r NHL- based on the P-I data

  Ref: Globe Newswire | Image: Merck 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions